HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
CERT Certara
- 14.190
- -0.060-0.42%
Close Feb 14 16:00 ET
2.28BMarket Cap-70.95P/E (TTM)
15.690High14.173Low2.07MVolume15.180Open14.250Pre Close30.67MTurnover1.86%Turnover RatioLossP/E (Static)160.99MShares19.87052wk High2.17P/B1.58BFloat Cap9.41052wk Low--Dividend TTM111.30MShs Float45.480Historical High--Div YieldTTM10.65%Amplitude9.410Historical Low14.782Avg Price1Lot Size
About Certara Company
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.
Company Profile
SymbolCERT
Company NameCertara
Listing DateDec 11, 2020
Issue Price23.00
Founded2017
CEODr. William F. Feehery, PhD
MarketNASDAQ
Employees1391
Fiscal Year Ends12-31
Address4 Radnor Corporate Center,Suite 350
CityRadnor
ProvincePennsylvania
CountryUnited States of America
Zip Code19087
Phone1-415-237-8772
Websitehttp://www.certara.com
Company Executives
- Name
- Position
- Salary
- Dr. William F. Feehery, PhD
- Director and Chief Executive Officer
- 7.81M
- Nicolette D. Sherman
- Chief Human Resources Officer
- --
- Leif E. Pedersen
- President and Chief Commercial Officer
- 2.14M
- John E. Gallagher
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- 4.24M
- Richard M. Traynor
- Senior Vice President and General Counsel
- --
- Dr. Robert Aspbury, PhD
- President, Certara Scientific Software
- 2.09M
- James E. Cashman, III
- Chairman of the Board
- 319.51K
- Patrick F Smith
- President, Integrated Drug Development
- 2.42M
- Dr. John V. W. Reynders
- Director
- --
- Nancy Killefer
- Independent Director
- 252.01K
- Cynthia Lynne Collins
- Independent Director
- 242.01K
- Matthew M. Walsh
- Independent Director
- 252.01K
- Eran Broshy
- Independent Director
- 252.01K
- Stephen M. McLean
- Independent Director
- --
- David Spaight
- Independent Director
- --
- Rosemary A. Crane, M.B.A.
- Independent Director
- 239.51K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025